Physician profile
Laura Braham
NPI 1770552556
$2,115.95
in general payments reported to CMS, 2019-2025
28 companies · $733 in 2025
The $733 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $136 · 2021: $61.11 · 2022: $12.06 · 2023: $354 · 2024: $510 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,596.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $312.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $233.04 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $212.10 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $176.08 | 2019-2025 | |
| Abbvie INC. | $131.89 | 2023-2025 | Qulipta |
| Phathom Pharmaceuticals, INC. | $121.05 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $114.21 | 2024-2025 | Ibsrela |
| Amgen INC. | $83.40 | 2019-2025 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.13 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $69.29 | 2023 | Resonate El Icd Vr |
| Glaxosmithkline, LLC. | $67.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $64.76 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.32 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $51.17 | 2019-2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $47.25 | 2019-2024 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.71 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $32.58 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $26.68 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $26.01 | 2019-2020 | |
| Sanofi Pasteur INC. | $25.69 | 2019-2022 | |
| Saluda Medical Americas, INC. | $24.06 | 2025 | Evoke |
| Novartis Pharmaceuticals Corporation | $23.23 | 2019 | |
| Axsome Therapeutics, INC. | $22.45 | 2025 | Auvelity |
| Amarin Pharma, INC. | $15.20 | 2019 | |
| Currax Pharmaceuticals LLC | $14.76 | 2020 | |
| Mylan Specialty L.P. | $14.50 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.81 | 2024 | |
| Zyla Life Sciences, INC. | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Braham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.